1
|
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V. Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation. Arthritis Rheumatol 2024; 76:751-762. [PMID: 38130019 DOI: 10.1002/art.42789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 12/12/2023] [Accepted: 12/19/2023] [Indexed: 12/23/2023]
Abstract
OBJECTIVE The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti-Ro60/SSA antibodies, whereas the significance of anti-Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti-Ro52/TRIM21 antibody status. METHODS Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52-/Ro60-), isolated anti-Ro52/TRIM21 positive (Ro52+), isolated anti-Ro60/SSA positive (Ro60+), and double-positive (Ro52+/Ro60+) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients. RESULTS In the DIApSS cohort, Ro52+/Ro60+ patients showed significantly more parotidomegaly (33.3% vs 0%-11%) along with higher β2-microglobulin (P = 0.0002), total immunoglobulin (P < 0.0001), and erythrocyte sedimentation rate levels (P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%-25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis (P = 0.046), inflammation (P = 0.005), hypergammaglobulinemia (P < 0.0001), positive RF (P < 0.0001), leukopenia (P = 0.004), and lymphopenia (P = 0.009) in Ro52+/Ro60+ patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities (P = 0.002). Transcriptome analysis linked anti-Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations. CONCLUSION These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies.
Collapse
Affiliation(s)
- Eléonore Bettacchioli
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Alain Saraux
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Alice Tison
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Divi Cornec
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Maryvonne Dueymes
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Nathan Foulquier
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Sophie Hillion
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| | | | | | | | | | - Valérie Devauchelle-Pensec
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France
| |
Collapse
|
2
|
Wendling D, Tabaa OA, Chevet B, Fakih O, Ghossan R, Hecquet S, Dernis E, Maheu E, Saraux A, Besson FL, Alegria GC, Cortet B, Fautrel B, Felten R, Morel J, Ottaviani S, Querellou-Lefranc S, Ramon A, Ruyssen-Witrand A, Seror R, Tournadre A, Foulquier N, Verlhac B, Verhoeven F, Devauchelle-Pensec V. Recommendations of the French Society of Rheumatology for the management in current practice of patients with Polymyalgia Rheumatica. Joint Bone Spine 2024:105730. [PMID: 38583691 DOI: 10.1016/j.jbspin.2024.105730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 03/25/2024] [Accepted: 03/26/2024] [Indexed: 04/09/2024]
Abstract
OBJECTIVE To develop recommendations for the routine management of patients with polymyalgia rheumatica (PMR) Methods: Following standard procedures, a systematic review of the literature by 5 supervised junior rheumatologists, based on the questions selected by the steering committee (5 senior rheumatologists), was used as the basis for working meetings, followed by a one-day plenary meeting with the working group (15 members), leading to the development of the wording and determination of the strength of the recommendations and the level of agreement of the experts. RESULTS Five general principles and 19 recommendations were drawn up. Three recommendations relate to diagnosis and the use of imaging, and 5 to the assessment of the disease, its activity and co-morbidities. Non-pharmacological therapies are the subject of one recommendation. Three recommendations concern initial treatment based on general corticosteroid therapy, 5 concern the reduction of corticosteroid therapy and follow-up, and 2 concern corticosteroid dependence and steroid-sparing treatments (anti-IL-6). CONCLUSION These recommendations take account of current data on PMR, with the aim of reducing exposure to corticosteroid therapy and its side effects in a fragile population. They are intended to be practical, to help practitioners in the day-to-day management of patients with PMR.
Collapse
Affiliation(s)
- Daniel Wendling
- Rhumatologie, CHU de Besançon et Université de Franche-Comté, Besançon, France.
| | - Omar Al Tabaa
- Rhumatologie, Hôpital Cochin, AP-HP, Paris, France; Rhumatologie, Hôpital NOVO, Pontoise, France
| | - Baptiste Chevet
- Université de Bretagne Occidentale (Univ Brest), Department of Rheumatology, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France, 29200 Brest, France
| | - Olivier Fakih
- Rhumatologie, CHU de Besançon et Université de Franche-Comté, Besançon, France
| | - Roba Ghossan
- Rhumatologie, Hôpital Cochin, AP-HP, Paris, France
| | | | | | - Emmanuel Maheu
- Service de Rhumatologie, Hôpital St Antoine, APHP, et cabinet médical, Paris, France
| | - Alain Saraux
- Université de Bretagne Occidentale (Univ Brest), Department of Rheumatology, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France, 29200 Brest, France
| | - Florent L Besson
- Service de Médecine Nucléaire-Imagerie Moléculaire, Hôpitaux Universitaires Paris-Saclay AP-HP, CHU Bicêtre, DMU SMART IMAGING, Le Kremlin-Bicêtre, France
| | | | - Bernard Cortet
- Service de Rhumatologie, CHU de Lille, 59037 Lille, France
| | - Bruno Fautrel
- AP-HP.Sorbonne Université, Service de Rhumatologie,GH Pitié Salpêtrière, INSERM UMRS 1136-5, Réseau de Recherche Clinique CRI-IMIDIATE, 75013 Paris, France
| | - Renaud Felten
- Service de Rhumatologie et Centre d'Investigation Clinique 1434, Hôpitaux Universitaires de Strasbourg, France
| | - Jacques Morel
- Service de Rhumatologie. CHU et Université de Montpellier, Montpellier, France
| | | | - Solène Querellou-Lefranc
- Nuclear Medicine department, University Hospital, Brest, France, University of Western Brittany (UBO), Brest, France, Inserm, Univ Brest, CHRU Brest, UMR 1304, GETBO, Brest cedex, France
| | - André Ramon
- Service de Rhumatologie, CHU Dijon Bourgogne, Dijon, France
| | - Adeline Ruyssen-Witrand
- Centre de rhumatologie, CHU de Toulouse, Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Team PEPSS « Pharmacologie En Population cohorteS et biobanqueS », Université Paul Sabatier Toulouse 3, Toulouse, France
| | - Raphaèle Seror
- Service de Rhumatologie, CHU Kremlin-Bicetre, APHP, Paris, France
| | - Anne Tournadre
- Rhumatologie CHU Clermont-Ferrand, Université Clermont Auvergne INRAe, France
| | - Nathan Foulquier
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France ; CHU de Brest, Brest, France
| | | | - Frank Verhoeven
- Rhumatologie, CHU de Besançon et Université de Franche-Comté, Besançon, France
| | - Valérie Devauchelle-Pensec
- Université de Bretagne Occidentale (Univ Brest), Department of Rheumatology, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France, 29200 Brest, France.
| |
Collapse
|
3
|
Gordon RA, Nguyen Y, Foulquier N, Beydon M, Gheita TA, Hajji R, Sahbudin I, Hoi A, Ng WF, Mendonça JA, Wallace DJ, Shea B, Bruyn GA, Goodman SM, Fisher BA, Baldini C, Torralba KD, Bootsma H, Akpek EK, Karakus S, Baer AN, Chakravarty SD, Terslev L, D'Agostino MA, Mariette X, DiRenzo D, Rasmussen A, Papas A, Montoya C, Arends S, Yusof MYM, Pintilie I, Warner BM, Hammitt KM, Strand V, Bouillot C, Tugwell P, Inanc N, Andreu JL, Wahren-Herlenius M, Devauchelle-Pensec V, Shiboski CH, Benyoussef A, Masli S, Lee AYS, Cornec D, Bowman S, Rischmueller M, McCoy SS, Seror R. The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation. Semin Arthritis Rheum 2024; 65:152378. [PMID: 38310657 PMCID: PMC10954392 DOI: 10.1016/j.semarthrit.2024.152378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 01/04/2024] [Accepted: 01/09/2024] [Indexed: 02/06/2024]
Abstract
Sjögren's disease (SjD) is a systemic autoimmune exocrinopathy with key features of dryness, pain, and fatigue. SjD can affect any organ system with a variety of presentations across individuals. This heterogeneity is one of the major barriers for developing effective disease modifying treatments. Defining core disease domains comprising both specific clinical features and incorporating the patient experience is a critical first step to define this complex disease. The OMERACT SjD Working Group held its first international collaborative hybrid meeting in 2023, applying the OMERACT 2.2 filter toward identification of core domains. We accomplished our first goal, a scoping literature review that was presented at the Special Interest Group held in May 2023. Building on the domains identified in the scoping review, we uniquely deployed multidisciplinary experts as part of our collaborative team to generate a provisional domain list that captures SjD heterogeneity.
Collapse
Affiliation(s)
- Rachael A Gordon
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, USA
| | - Yann Nguyen
- Department of Rheumatology, National Reference Center for Auto-immune Diseases, Sjogren's ERN Reconnect Center, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, Paris, France
| | | | - Maxime Beydon
- Department of Rheumatology, National Reference Center for Auto-immune Diseases, Sjogren's ERN Reconnect Center, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, Paris, France
| | - Tamer A Gheita
- Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Raouf Hajji
- Internal Medicine Department, Sidi Bouzid Hospital, University of Sousse, Medicine Faculty of Sousse, 4000, Sousse, Tunisia; International Medical Community (IMC), Via Nomentana, 403, Rome, Lazio 00162, Italy
| | - Ilfita Sahbudin
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | | | - Wan-Fai Ng
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust & Newcastle University, Newcastle upon Tyne, UK
| | - Jose Alexandre Mendonça
- Postgraduate Program in Health Sciences/Rheumatology/Ultrasonography Service, Pontifical Catholic University of Campinas, SP, Brazil
| | - Daniel J Wallace
- Cedars-Sinai Medical Center, Los Angeles, California, USA; University of California, David Geffen School of Medicine, Los Angeles, California, USA
| | - Beverley Shea
- Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - George Aw Bruyn
- Department of Rheumatology, Tergooi MC hospitals, Hilversum, the Netherlands
| | - Susan M Goodman
- Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | - Benjamin A Fisher
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Chiara Baldini
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - Karina D Torralba
- Division of Rheumatology, Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California, USA; Division of Rheumatology, Department of Medicine, University of California Riverside School of Medicine, Riverside, California, USA
| | - Hendrika Bootsma
- Department Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Esen K Akpek
- Ocular Surface Disease Clinic, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Sezen Karakus
- Ocular Surface Disease Clinic, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Alan N Baer
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Soumya D Chakravarty
- Janssen Scientific Affairs, LLC, Horsham, PA, USA, Drexel University College of Medicine, Philadelphia, PA, USA
| | - Lene Terslev
- Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, The University of Copenhagen, Copenhagen, Denmark
| | - Maria-Antonietta D'Agostino
- Rheumatology Department, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, IRCSS, Rome, Italy
| | - Xavier Mariette
- Department of Rheumatology, National Reference Center for Auto-immune Diseases, Sjogren's ERN Reconnect Center, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, Paris, France
| | - Dana DiRenzo
- Rheumatology Department, University of Pennsylvania, Philadelphia, PA, USA
| | - Astrid Rasmussen
- Genes and Human Disease Program, Oklahoma Medical Research Foundation. Oklahoma City, OK, USA
| | - Athena Papas
- Tufts School of Dental Medicine Boston, Massachusetts, USA
| | - Cristina Montoya
- Registered Dietitian Active patient volunteer for the Sjogren's Society of Canada, Canada
| | - Suzanne Arends
- Department Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Md Yuzaiful Md Yusof
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, UK
| | - Ionut Pintilie
- Rheumatology Department, Connect Medical, Piatra Neamt, Romania
| | - Blake M Warner
- Salivary Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
| | | | - Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA
| | | | - Peter Tugwell
- Dept of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Nevsun Inanc
- Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey
| | - José Luis Andreu
- Rheumatology Department, University Hospital Puerta de Hierro, Majadahonda, Spain
| | - Marie Wahren-Herlenius
- Division of Rheumatology, Department of Medicine, Karolinska Institute, Sweden; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Norway
| | | | - Caroline H Shiboski
- Department of Orafacial Sciences, University of California San Francisco, San Francisco, CA, USA
| | - Anas Benyoussef
- Ophthalmology Department, centre hospitalier universitaire de Brest, 2, avenue Foch, 29609 Brest cedex, France
| | | | - Adrian Y S Lee
- Department of Clinical Immunology & Allergy, Westmead Hospital, Westmead, NSW, Australia
| | - Divi Cornec
- LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France
| | - Simon Bowman
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK; Institute of Inflammation & Ageing, University of Birmingham, Birmingham, UK, Rheumatology Department, University Hospitals Birmingham, Birmingham, UK and Rheumatology Department, Milton Keynes University Hospital, Milton Keynes, UK
| | - Maureen Rischmueller
- The Queen Elizabeth Hospital, Woodville and University of Adelaide, Adelaide, Australia
| | - Sara S McCoy
- Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, USA.
| | - Raphaele Seror
- Department of Rheumatology, National Reference Center for Auto-immune Diseases, Sjogren's ERN Reconnect Center, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, Paris, France
| |
Collapse
|
4
|
Nguyen Y, Beydon M, Foulquier N, Gordon R, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, McCoy SS, Cornec D, Seror R. Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group. Semin Arthritis Rheum 2024; 65:152385. [PMID: 38340608 DOI: 10.1016/j.semarthrit.2024.152385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 12/29/2023] [Accepted: 01/03/2024] [Indexed: 02/12/2024]
Abstract
OBJECTIVES Sjögren's disease (SjD) is a heterogenous disease with a wide range of manifestations, ranging from symptoms of dryness, fatigue, and pain, to systemic involvement. Considerable advances have been made to evaluate systemic activity or patient-reported outcomes, but most of the instruments were not able to assess all domains of this multifaceted disease. The aim of this scoping review was to generate domains that have been assessed in randomized controlled trials, as the first phase of the Outcome Measures in Rheumatology (OMERACT) process of core domain set development. METHODS We systematically searched Medline (Pubmed) and EMBASE between 2002 and March 2023 to identify all randomized controlled trials assessing relevant domains, using both a manual approach and an artificial intelligence software (BIBOT) that applies natural language processing to automatically identify relevant abstracts. Domains were mapped to core areas, as suggested by the OMERACT 2.1 Filter. RESULTS Among the 5,420 references, we included 60 randomized controlled trials, focusing either on overall disease manifestations (53%) or on a single organ/symptom: dry eyes (17%), xerostomia (15%), fatigue (12%), or pulmonary function (3%). The most frequently assessed domains were perceived dryness (52% for overall dryness), fatigue (57%), pain (52%), systemic disease activity (45%), lacrimal gland function (47%) and salivary function (55%), B-cell activation (60%), and health-related quality of life (40%). CONCLUSION Our scoping review highlighted the heterogeneity of SjD, in the study designs and domains. This will inform the OMERACT SjD working group to select the most appropriate core domains to be used in SjD clinical trials and to guide the future agenda for outcome measure research in SjD.
Collapse
Affiliation(s)
- Yann Nguyen
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM), UMR1184, Université Paris-Saclay, Le Kremlin Bicêtre, Paris, France
| | - Maxime Beydon
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | - Rachael Gordon
- Department of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | | | | - Simon J Bowman
- Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
| | - Xavier Mariette
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM), UMR1184, Université Paris-Saclay, Le Kremlin Bicêtre, Paris, France
| | - Sara S McCoy
- Division of Rheumatology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, USA
| | - Divi Cornec
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France; INSERM, UMR1227, Lymphocytes B, Autoimmunité et Immunothérapies, Université de Bretagne Occidentale, Service de Rhumatologie, CHU de Brest, Brest, France
| | - Raphaèle Seror
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM), UMR1184, Université Paris-Saclay, Le Kremlin Bicêtre, Paris, France.
| |
Collapse
|
5
|
Bettacchioli E, Saraux A, Foulquier N, Cornec D, Devauchelle-Pensec V. Reply. Arthritis Rheumatol 2024. [PMID: 38321927 DOI: 10.1002/art.42820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Accepted: 01/24/2024] [Indexed: 02/08/2024]
Affiliation(s)
- Eléonore Bettacchioli
- Lymphocytes B, Autoimmunité et Immunothérapies, UMR1227, INSERM, University of Western Brittany and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Alain Saraux
- Lymphocytes B, Autoimmunité et Immunothérapies, UMR1227, INSERM, University of Western Brittany and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Nathan Foulquier
- Lymphocytes B, Autoimmunité et Immunothérapies, UMR1227, INSERM, University of Western Brittany and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Divi Cornec
- Lymphocytes B, Autoimmunité et Immunothérapies, UMR1227, INSERM, University of Western Brittany and Centre Hospitalier Universitaire de Brest, Brest, France
| | - Valérie Devauchelle-Pensec
- Lymphocytes B, Autoimmunité et Immunothérapies, UMR1227, INSERM, University of Western Brittany and Centre Hospitalier Universitaire de Brest, Brest, France
| |
Collapse
|
6
|
Scuiller Y, Hemon P, Le Rochais M, Pers JO, Jamin C, Foulquier N. YOUPI: Your powerful and intelligent tool for segmenting cells from imaging mass cytometry data. Front Immunol 2023; 14:1072118. [PMID: 36936977 PMCID: PMC10019895 DOI: 10.3389/fimmu.2023.1072118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 02/13/2023] [Indexed: 03/06/2023] Open
Abstract
The recent emergence of imaging mass cytometry technology has led to the generation of an increasing amount of high-dimensional data and, with it, the need for suitable performant bioinformatics tools dedicated to specific multiparametric studies. The first and most important step in treating the acquired images is the ability to perform highly efficient cell segmentation for subsequent analyses. In this context, we developed YOUPI (Your Powerful and Intelligent tool) software. It combines advanced segmentation techniques based on deep learning algorithms with a friendly graphical user interface for non-bioinformatics users. In this article, we present the segmentation algorithm developed for YOUPI. We have set a benchmark with mathematics-based segmentation approaches to estimate its robustness in segmenting different tissue biopsies.
Collapse
Affiliation(s)
| | | | | | | | - Christophe Jamin
- LBAI, UMR 1227, Univ Brest, Inserm, Brest, France
- CHU de Brest, Brest, France
- *Correspondence: Christophe Jamin,
| | | |
Collapse
|
7
|
Foulquier N, Le Dantec C, Bettacchioli E, Jamin C, Alarcón‐Riquelme ME, Pers J, Alarcón-Riquelme ME, Pers JO. Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases. Arthritis Rheumatol 2022; 74:1706-1719. [PMID: 35635731 PMCID: PMC9804576 DOI: 10.1002/art.42243] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 04/14/2022] [Accepted: 05/17/2022] [Indexed: 01/05/2023]
Abstract
OBJECTIVE Anti-Ro autoantibodies are among the most frequently detected extractable nuclear antigen autoantibodies, mainly associated with primary Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and undifferentiated connective tissue disease (UCTD). This study was undertaken to determine if there is a common signature for all patients expressing anti-Ro 60 autoantibodies regardless of their disease phenotype. METHODS Using high-throughput multiomics data collected from the cross-sectional cohort in the PRECISE Systemic Autoimmune Diseases (PRECISESADS) study Innovative Medicines Initiative (IMI) project (genetic, epigenomic, and transcriptomic data, combined with flow cytometry data, multiplexed cytokines, classic serology, and clinical data), we used machine learning to assess the integrated molecular profiling of 520 anti-Ro 60+ patients compared to 511 anti-Ro 60- patients with primary SS, patients with SLE, and patients with UCTD, and 279 healthy controls. RESULTS The selected clinical features for RNA-Seq, DNA methylation, and genome-wide association study data allowed for a clear distinction between anti-Ro 60+ and anti-Ro 60- patients. The different features selected using machine learning from the anti-Ro 60+ patients constituted specific signatures when compared to anti-Ro 60- patients and healthy controls. Remarkably, the transcript Z score of 3 genes (ATP10A, MX1, and PARP14), presenting with overexpression associated with hypomethylation and genetic variation and independently identified using the Boruta algorithm, was clearly higher in anti-Ro 60+ patients compared to anti-Ro 60- patients regardless of disease type. Our findings demonstrated that these signatures, enriched in interferon-stimulated genes, were also found in anti-Ro 60+ patients with rheumatoid arthritis and those with systemic sclerosis and remained stable over time and were not affected by treatment. CONCLUSION Anti-Ro 60+ patients present with a specific inflammatory signature regardless of their disease type, suggesting that a dual therapeutic approach targeting both Ro-associated RNAs and anti-Ro 60 autoantibodies should be considered.
Collapse
Affiliation(s)
- Nathan Foulquier
- B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227Université de Brest, INSERMBrestFrance
| | - Christelle Le Dantec
- B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227Université de Brest, INSERMBrestFrance
| | - Eleonore Bettacchioli
- B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227Université de Brest, INSERMBrestFrance
| | - Christophe Jamin
- B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227Université de Brest, INSERM, and University Hospital of BrestBrestFrance
| | | | - Jacques‐Olivier Pers
- B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227Université de Brest, INSERM, and University Hospital of BrestBrestFrance
| | - Marta E Alarcón-Riquelme
- Department of Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
| | - Jacques-Olivier Pers
- LBAI, UMR1227, Univ Brest, Inserm, Labex IGO, Brest, France.,CHU de Brest, Brest, France
| |
Collapse
|
8
|
Casy T, Grasseau A, Charras A, Rouvière B, Pers JO, Foulquier N, Saraux A. Assessing the robustness of clinical trials by estimating Jadad's score using artificial intelligence approaches. Comput Biol Med 2022; 148:105851. [DOI: 10.1016/j.compbiomed.2022.105851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 04/25/2022] [Accepted: 05/23/2022] [Indexed: 11/15/2022]
|
9
|
Foulquier N, Le Dantec C, Bettacchioli E, Jamin C, Alarcon-Riquelme M, Pers JO. OP0009 MACHINE LEARNING IDENTIFIES A COMMON SIGNATURE FOR ANTI-SSA/Ro60 Antibody Expression Across Autoimmune Diseases. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundAnti-SSA/Ro autoantibodies are among the most frequently detected extractable nuclear antigen autoantibodies and have mainly been associated with primary Sjögren’s syndrome (pSS), systemic lupus erythematosus (SLE) and undifferentiated connective tissue disease (UCTD).ObjectivesIs there a common signature to all patients expressing anti-Ro60 autoantibodies regardless of their disease phenotype?MethodsUsing high-throughput multi-omics data collected within the cross-sectional cohort from the PRECISESADS IMI project [1] (genetic, epigenomic, transcriptomic, combined with flow cytometric data, multiplexed cytokines, classical serology and clinical data), we assessed by machine learning the integrated molecular profiling of 520 anti-Ro60-positive (anti-Ro60+) compared to 511 anti-Ro60-negative (anti-Ro60-) patients with pSS, SLE and UCTD, and 279 healthy controls (HCs).ResultsThe selected features for RNA-Seq, DNA methylation and GWAS data allowed a clear separation between anti-Ro60+ and anti-Ro60- patients. These results demonstrate that the different features selected by machine learning from the anti-Ro60+ patients constitute specific signatures when compared to anti-Ro60- patients and HCs. Remarkably, the gene transcript z-score of three genes (ATP10A, MX1 and PARP14), presenting an overexpression associated with a hypomethylation and genetic variation, and independently identified by the Boruta algorithm, was clearly higher in anti-Ro60+ patients compared to anti-Ro60- patients in all the diseases (Figure 1). Finally, we demonstrate that these signatures, enriched in interferon stimulated genes, were also found in anti-Ro60+ patients with rheumatoid arthritis and systemic sclerosis.Figure 1.Three genes common to RNA-Seq, DNA methylation and GWAS analysis characterize anti-Ro60+ patients. (A) ATP10/MX1/PARP14 z-score analyses were performed for 731 patients and 254 HCs according to anti-Ro60 expression. (B) ATP10/MX1/PARP14 z-score analyses were performed for 286 pSS, 351 SLE and 94 UCTD patients and 254 HCs. Two-tailed pairwise Wilcoxon-rank sum test results are shown. Plots show median, with error bars indicating ± interquartile range. (pSS: primary Sjögren’s syndrome, SLE: systemic lupus erythematosus, UCTD: undifferentiated connective tissue disease, HCs: healthy controls).ConclusionAnti-Ro60+ patients present a specific inflammatory signature regardless of their disease suggesting that a dual approach targeting both Ro-associated RNAs and anti-Ro60 autoantibodies should be considered.References[1]Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis Rheumatol Hoboken NJ. 2021 Jun;73(6):1073–85FundingThe research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under the Grant Agreement Number 115565 (PRECISESADS project), resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and EFPIA companies’ in-kind contribution.AcknowledgementsThe study has been conducted thank to the contribution of the PRECISESADS clinical consortium and the PRECISESADS flow cytometry consortium.Disclosure of InterestsNone declared.
Collapse
|
10
|
Laigle L, Le Dantec C, Soret P, Desvaux E, Hubert S, Foulquier N, Moingeon P, Guedj M, Pers JO. [Sjögren's syndrome: Towards precision medicine]. Med Sci (Paris) 2022; 38:148-151. [PMID: 35179468 DOI: 10.1051/medsci/2021258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Laurence Laigle
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | | | - Perrine Soret
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | - Emiko Desvaux
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | - Sandra Hubert
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | - Nathan Foulquier
- LBAI, Inserm UMR1227, Univ Brest, Labex IGO, 5 avenue Foch, 29609 Brest, France
| | - Philippe Moingeon
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | - Mickaël Guedj
- Institut de recherches internationales Servier, 50 rue Carnot, 92284 Suresnes Cedex, France
| | - Jacques-Olivier Pers
- LBAI, Inserm UMR1227, Univ Brest, Labex IGO, 5 avenue Foch, 29609 Brest, France - CHU de Brest, 29609 Brest, France
| |
Collapse
|
11
|
Foulquier N, Chevet B, Carvajal Alegria G, Saraux L, Devauchelle-Pensec V, Redou P, Saraux A. Towards a universal definition of disease activity score thresholds: the AS135 score. Clin Exp Rheumatol 2022; 41:1009-1016. [PMID: 36062781 DOI: 10.55563/clinexprheumatol/30qjog] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 07/11/2022] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Many study groups have developed scores to reflect disease activity. The result of this fragmented process is a multitude of disease activity scores, even for a single disease. We aimed to identify and standardise disease activity scores in rheumatologyMETHODS: We conducted a literature review on disease activity criteria using both a manual approach and in-house computer software (BIBOT) that applies natural language processing to automatically identify and interpret important words in abstracts published in English between 1.1.1975 and 31.12.2018. We selected activity scores with cut-off values divided into four classes (remission and low, moderate and high disease activity). We used a linear interpolation to map disease activity scores to our new score, the AS135, and developed a smartphone application to perform the conversion. RESULTS A total of 108 activity criteria from various fields were identified, but it was in rheumatology that we found the most pronounced separation into four classes. We built the AS135 score modification for each selected score using a linear interpolation of the existing criteria. The score modification was defined on the interval [0,10], and values of 1, 3 and 5 were used as thresholds. These arbitrary thresholds were then associated with the thresholds of the existing criteria, and an interpolation was calculated, allowing conversion of the existing criteria into the AS135 criterion. Finally, we created a mobile application. CONCLUSIONS We developed an application for clinicians that enables the use of a single disease activity score for different inflammatory rheumatic diseases using an intuitive scale.
Collapse
Affiliation(s)
- Nathan Foulquier
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, and LATIM, Laboratoire de Traitement de l’Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France
| | - Baptiste Chevet
- Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | - Guillermo Carvajal Alegria
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, and Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | - Léa Saraux
- Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | - Valérie Devauchelle-Pensec
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, and Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | - Pascal Redou
- LATIM, Laboratoire de Traitement de l’Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France
| | - Alain Saraux
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, and Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France.
| |
Collapse
|
12
|
Tison A, Preuss P, Leleu C, Robin F, Le Pluart A, Vix J, Le Mélédo G, Goupille P, Gervais E, Cormier G, Albert JD, Perdriger A, Bouvard B, Berthelot JM, Foulquier N, Saraux A. Publisher Correction: Rheumatological features of Whipple disease. Sci Rep 2021; 11:16197. [PMID: 34349122 PMCID: PMC8339113 DOI: 10.1038/s41598-021-94889-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Alice Tison
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, CHU Brest, LabEx IGO, Brest, France.,Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | | | | | - François Robin
- Rennes, Service de Rhumatologie, Univ Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer), 35000, Rennes, France
| | | | | | - Guillaume Le Mélédo
- Rheumatology Department, University Hospital of Tours, EA 7501, GICC, University of Tours, Tours, France
| | - Philippe Goupille
- Rheumatology Department, University Hospital of Tours, EA 7501, GICC, University of Tours, Tours, France
| | | | | | - Jean-David Albert
- Rennes, Service de Rhumatologie, Univ Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer), 35000, Rennes, France
| | - Aleth Perdriger
- Rennes, Service de Rhumatologie, Univ Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer), 35000, Rennes, France
| | | | | | - Nathan Foulquier
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, CHU Brest, LabEx IGO, Brest, France
| | - Alain Saraux
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, CHU Brest, LabEx IGO, Brest, France. .,Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France. .,Rheumatology Unit, Hôpital de la Cavale Blanche, BP 824, 29609, Brest cedex, France.
| |
Collapse
|
13
|
Soret P, Le Dantec C, Desvaux E, Foulquier N, Chassagnol B, Hubert S, Jamin C, Barturen G, Desachy G, Devauchelle-Pensec V, Boudjeniba C, Cornec D, Saraux A, Jousse-Joulin S, Barbarroja N, Rodríguez-Pintó I, De Langhe E, Beretta L, Chizzolini C, Kovács L, Witte T, Bettacchioli E, Buttgereit A, Makowska Z, Lesche R, Borghi MO, Martin J, Courtade-Gaiani S, Xuereb L, Guedj M, Moingeon P, Alarcón-Riquelme ME, Laigle L, Pers JO. A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. Nat Commun 2021; 12:3523. [PMID: 34112769 PMCID: PMC8192578 DOI: 10.1038/s41467-021-23472-7] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 04/30/2021] [Indexed: 02/08/2023] Open
Abstract
There is currently no approved treatment for primary Sjögren's syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity in the clinical manifestation and pathophysiology of the disease. Finding common molecular signatures among patient subgroups could improve our understanding of disease etiology, and facilitate the development of targeted therapeutics. Here, we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren's syndrome patients based on the multi-omic profiling of whole blood samples from a European cohort of over 300 patients, and a similar number of age and gender-matched healthy volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cytometry data, combined with clinical parameters, we identify four groups of patients with distinct patterns of immune dysregulation. The biomarkers we identify can be used by machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation of response to treatments in clinical trials.
Collapse
Affiliation(s)
- Perrine Soret
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | | | - Emiko Desvaux
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France
| | | | - Bastien Chassagnol
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Sandra Hubert
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Christophe Jamin
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France
- CHU de Brest, Brest, France
| | - Guillermo Barturen
- Department of Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
| | - Guillaume Desachy
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | | | - Cheïma Boudjeniba
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Divi Cornec
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France
- CHU de Brest, Brest, France
| | - Alain Saraux
- LBAI, UMR1227, Univ Brest, Inserm, Brest, France
- CHU de Brest, Brest, France
| | | | - Nuria Barbarroja
- Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain
| | - Ignasi Rodríguez-Pintó
- Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain
| | - Ellen De Langhe
- Skeletal Biology and Engineering Research Center, KU Leuven and Division of Rheumatology, UZ Leuven, Belgium
| | - Lorenzo Beretta
- Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
| | - Carlo Chizzolini
- Immunology & Allergy, University Hospital and School of Medicine, Geneva, Switzerland
| | | | - Torsten Witte
- Klinik für Immunologie und Rheumatologie, Medical University Hannover, Hannover, Germany
| | | | - Anne Buttgereit
- Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany
| | - Zuzanna Makowska
- Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany
| | - Ralf Lesche
- Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany
| | | | - Javier Martin
- Institute of Parasitology and Biomedicine López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, Spain
| | - Sophie Courtade-Gaiani
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Laura Xuereb
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Mickaël Guedj
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Philippe Moingeon
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | - Marta E Alarcón-Riquelme
- Department of Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
| | - Laurence Laigle
- Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development, Suresnes, France
| | | |
Collapse
|
14
|
Foulquier N, Chevet B, Carvajal G, Saraux L, Devauchelle-Pensec V, Redou P, Saraux A. Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint). JMIR Med Inform 2020. [DOI: 10.2196/24493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Foulquier N, Redou P, Pers JO, Saraux A. New criteria and new methodological tools for devising criteria sets of inflammatory rheumatic diseases. Clin Exp Rheumatol 2020; 38:776-782. [PMID: 32105592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 12/09/2019] [Indexed: 06/10/2023]
Abstract
Rheumatologists use classification criteria to separate patients with inflammatory rheumatic diseases (IRD). They change over time, and the concepts of the diseases also change. The paradigm is currently moving as the goal of classification in the future will be more to select which patients may be relevant for a specific treatment rather than to describe their characteristics. Therefore, the challenge will be to reclassify multifactorial diseases on the basis of their biological mechanisms rather than their clinical phenotype. Currently, various projects are trying to reclassify diseases using bioinformatics approaches and in the near future the use of advanced machine learning algorithms with large omics datasets could lead to new classification models not only based on a clinical phenotype but also on complex biological profile and common sensitivity to targeted treatment. These models would highlight common biological pathways between patients classified in the same cluster and provide a deep understanding of the mechanisms involved in the patient's clinical phenotype. Such approaches would ultimately lead to classification models that rely more on biological causes than on symptoms. This overview on current classification of subgroups of IRD summarises the classification criteria that we use routinely, and how we will classify IRD in the future using bioinformatics and artificial intelligence techniques.
Collapse
Affiliation(s)
- Nathan Foulquier
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest; and LATIM, Laboratoire de Traitement de l'Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France
| | - Pascal Redou
- LATIM, Laboratoire de Traitement de l'Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France
| | - Jacques Olivier Pers
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, France
| | - Alain Saraux
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest; and Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France.
| |
Collapse
|
16
|
Foulquier N, Chevet B, Carvajal Alegria G, Saraux L, Devauchelle-Pensec V, Redou P, Saraux A. THU0617-HPR TOWARDS A UNIVERSAL DEFINITION OF DISEASE ACTIVITY SCORES THRESHOLDS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:For rheumatologists monitoring patients with various diseases and dealing with multiple scores with different maximum values (9 for RA-DAS, 6.4 for AS-DAS and 60 for PMR-AS) and values thresholds to characterize the different levels of disease activity (low, intermediate and high) can be a tedious task. The same problematic could arise in other specialty than rheumatology. Normalization of these scores seems to be necessary to facilitate daily clinical practice (1).Objectives:To indentify and standardize scores of activity of inflammatory diseases.Methods:We conducted a literature review on activity criteria using both a manual approach and the BIBOT software (2) published in English between 1.1.1975 and 31.12.2018. Within all extracted disease activity scores, we selected those with cut off values in four classes (remission, low, moderate and high disease activity). We used a linear interpolation to map all these disease activity scores to our new score, the AS-135, and developed a smart-phone application to perform the conversion automatically.Results:1068 articles were analyzed by BIBOT, 86 were excluded on the basis of the language used for their writing and 11 were excluded on the basis of their publication date. 599 were selected based on their titles, abstracts and keywords. 108 activity criteria from various fields (rheumatology, dermatology, gastroenterology, psychiatry, neurology and pneumology) were identified, but it is in rheumatology that we find separation into four classes. 10 scores met our inclusion criteria and were implemented in the Android app. These are: DAS28 (ESR), DAS28 (CRP), SDAI, ASDAS (ESR), ASDAS (CRP), ESSDAI, SLEDAI-2K, DAPSA, PMR-AS (ESR) and PMR-AS (CRP). We built the AS135 score modification for each selected score using a linear interpolation of the existing criteria. It was defined on the interval [0,10] and values 1, 3 and 5 were used as thresholds. These arbitrary thresholds are then associated with the thresholds of the existing criteria and an interpolation can be calculated, allowing the conversion of the existing criteria into AS135 criterion. We have finally created a mobile application that allows each user to obtain both the original value of the activity criterion.Conclusion:We have created a mobile application that allows any user to obtain in a simple way the level of disease activity, whatever the criterion used to describe it, since the application returns, in addition to the value of the activity criterion calculated from data returned by the physician, the transformation of this value into AS135 criterion and its interpretation in terms of level of activity of the pathology. The application is now available for Android devices and we plan to start developing a version for iOS devices.References:[1]Saraux L, Devauchelle-Pensec V, Saraux A. Plea for standardization of disease activity scores. Rheumatol Oxf Engl. 2019 Aug 1;58(8):1500–1[2]Orgeolet L, Foulquier N, Misery L, Redou P, Pers J-O, Devauchelle-Pensec V, et al. Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren’s syndrome. Rheumatol Oxf Engl. 2019 Aug 31;Disclosure of Interests:None declared
Collapse
|
17
|
Orgeolet L, Foulquier N, Misery L, Redou P, Pers JO, Devauchelle-Pensec V, Saraux A. Utilisation de l’intelligence artificielle pour la revue systématique de la littérature portant sur les manifestations cutanées du syndrome de Gougerot–Sjögren primitif. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Orgeolet L, Foulquier N, Misery L, Redou P, Pers JO, Devauchelle-Pensec V, Saraux A. Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren’s syndrome. Rheumatology (Oxford) 2019; 59:811-819. [DOI: 10.1093/rheumatology/kez370] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 07/09/2019] [Indexed: 01/12/2023] Open
Abstract
Abstract
Objectives
Manual systematic literature reviews are becoming increasingly challenging due to the sharp rise in publications. The primary objective of this literature review was to compare manual and computer software using artificial intelligence retrieval of publications on the cutaneous manifestations of primary SS, but we also evaluated the prevalence of cutaneous manifestations in primary SS.
Methods
We compared manual searching and searching with the in-house computer software BIbliography BOT (BIBOT) designed for article retrieval and analysis. Both methods were used for a systematic literature review on a complex topic, i.e. the cutaneous manifestations of primary SS. Reproducibility was estimated by computing Cohen’s κ coefficients and was interpreted as follows: slight, 0–0.20; fair, 0.21–0.40; moderate, 0.41–0.60; substantial, 0.61–0.80; and almost perfect, 0.81–1.
Results
The manual search retrieved 855 articles and BIBOT 1042 articles. In all, 202 articles were then selected by applying exclusion criteria. Among them, 155 were retrieved by both methods, 33 by manual search only, and 14 by BIBOT only. Reliability (κ = 0.84) was almost perfect. Further selection was performed by reading the 202 articles. Cohort sizes and the nature and prevalence of cutaneous manifestations varied across publications. In all, we found 52 cutaneous manifestations reported in primary SS patients. The most described ones were cutaneous vasculitis (561 patients), xerosis (651 patients) and annular erythema (215 patients).
Conclusion
Among the final selection of 202 articles, 155/202 (77%) were found by the two methods but BIBOT was faster and automatically classified the articles in a chart. Combining the two methods retrieved the largest number of publications.
Collapse
Affiliation(s)
- Laure Orgeolet
- Dermatology Unit, UMR 1101, IBRBS, Université de Brest, Inserm, CHU
| | - Nathan Foulquier
- LATIM, Laboratoire de Traitement de l’Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU
| | - Laurent Misery
- Dermatology Unit, UMR 1101, IBRBS, Université de Brest, Inserm, CHU
| | - Pascal Redou
- LATIM, Laboratoire de Traitement de l’Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU
| | - Jacques-Olivier Pers
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO
| | - Valérie Devauchelle-Pensec
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO
- Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| | - Alain Saraux
- UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO
- Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France
| |
Collapse
|
19
|
Foulquier N, Redou P, Saraux A. How Health Information Technologies and Artificial Intelligence May Help Rheumatologists in Routine Practice. Rheumatol Ther 2019; 6:135-138. [PMID: 31028546 PMCID: PMC6513911 DOI: 10.1007/s40744-019-0154-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Indexed: 01/16/2023] Open
Affiliation(s)
- Nathan Foulquier
- Laboratoire de Traitement de l'Information Médicale (LATIM), UMR 1101, Brest Institute of Biological Research (IBRBS), Inserm, Université de Brest-Centre Hospitalier Universitaire, Brest, France
| | - Pascal Redou
- Laboratoire de Traitement de l'Information Médicale (LATIM), UMR 1101, Brest Institute of Biological Research (IBRBS), Inserm, Université de Brest-Centre Hospitalier Universitaire, Brest, France
| | - Alain Saraux
- Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), Université de Brest-Centre Hospitalier Universitaire, Brest, France.
- UMR 1227, Lymphocytes B et Autoimmunité, Inserm, Université de Brest-Centre Hospitalier Universitaire, Brest, France.
- LabEx IGO, Brest, France.
| |
Collapse
|
20
|
Foulquier N, Redou P, Le Gal C, Rouvière B, Pers JO, Saraux A. Pathogenesis-based treatments in primary Sjogren's syndrome using artificial intelligence and advanced machine learning techniques: a systematic literature review. Hum Vaccin Immunother 2018; 14:2553-2558. [PMID: 29771635 DOI: 10.1080/21645515.2018.1475872] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Big data analysis has become a common way to extract information from complex and large datasets among most scientific domains. This approach is now used to study large cohorts of patients in medicine. This work is a review of publications that have used artificial intelligence and advanced machine learning techniques to study physio pathogenesis-based treatments in pSS. A systematic literature review retrieved all articles reporting on the use of advanced statistical analysis applied to the study of systemic autoimmune diseases (SADs) over the last decade. An automatic bibliography screening method has been developed to perform this task. The program called BIBOT was designed to fetch and analyze articles from the pubmed database using a list of keywords and Natural Language Processing approaches. The evolution of trends in statistical approaches, sizes of cohorts and number of publications over this period were also computed in the process. In all, 44077 abstracts were screened and 1017 publications were analyzed. The mean number of selected articles was 101.0 (S.D. 19.16) by year, but increased significantly over the time (from 74 articles in 2008 to 138 in 2017). Among them only 12 focused on pSS but none of them emphasized on the aspect of pathogenesis-based treatments. To conclude, medicine progressively enters the era of big data analysis and artificial intelligence, but these approaches are not yet used to describe pSS-specific pathogenesis-based treatment. Nevertheless, large multicentre studies are investigating this aspect with advanced algorithmic tools on large cohorts of SADs patients.
Collapse
Affiliation(s)
- Nathan Foulquier
- a LATIM, Laboratoire de Traitement de l'Information Médicale, Université de Brest, Inserm, CHU Brest , Brest , France.,b Lymphocytes B et Autoimmunité Université de Brest, Inserm, CHU Brest, LabEx IGO , Brest , France
| | - Pascal Redou
- a LATIM, Laboratoire de Traitement de l'Information Médicale, Université de Brest, Inserm, CHU Brest , Brest , France
| | - Christophe Le Gal
- a LATIM, Laboratoire de Traitement de l'Information Médicale, Université de Brest, Inserm, CHU Brest , Brest , France
| | - Bénédicte Rouvière
- b Lymphocytes B et Autoimmunité Université de Brest, Inserm, CHU Brest, LabEx IGO , Brest , France.,c Internal Medicine Unit, CHU , Brest , France
| | | | - Alain Saraux
- c Internal Medicine Unit, CHU , Brest , France.,d Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU , Brest , France
| |
Collapse
|